Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2005-12-20
2005-12-20
Li, Ruixiang (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C514S012200, C530S324000
Reexamination Certificate
active
06977077
ABSTRACT:
The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracure, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fracture, and/or reduce the incidence of non-vertebral fracture.
REFERENCES:
patent: 4086196 (1978-04-01), Tregear
patent: 4698328 (1987-10-01), Neer et al.
patent: 08073376 (1996-03-01), None
patent: 08073376 (1996-03-01), None
patent: 08310965 (1996-11-01), None
patent: 98/14478 (1998-04-01), None
patent: 99/12561 (1999-03-01), None
Hirano T, et al., “Anabolic Effects of Human Biosynthetic Parathyroid Hormone Fragment (1034), LY333334, on Remodeling and Mechanical Properties of Cortical Bone in Rabbits,”Journal of Bone and Mineral Research, vol. 14, No. 4, 536-545 (1999).
Lindsay, R. et al., “Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis,”The Lancet, vol. 350, 550-555 (1997).
Macgill, K. et al., “Vascular Effects of PTHrP (1-34) and PTH (1-34) in the Human Fetal-Placental Circulation,”Placenta, vol. 18, 587-592 (1997).
Lindsay, R. et al., “Subcutaneous Administration of the Amino-Terminal Fragment of Human Parathyroid Hormone- (1-34): Kinetics and Biochemical Response in Estrogenized Osteoporotic Patents,”Journal of Clinical Endocrinology and Metabolism, vol. 77, No. 6, 1535-1539 (1993).
Lane, N. et al., “Parathyroid Hormone Treatment Can Reverse Corticosteroid-Induced Osteoporosis,”J. Clin. Invest.,vol. 102, No. 8, 1627-1633 (Oct. 1998).
Cosman F. et al., “Is Parathyroid Hormone a Therapeutic Option for Osteoporosis? A Review of the Clinical Evidence,”Calcified Tissue International, vol. 62, 475-480 (1998).
Hesch, R.D. et al., “Results of a Stimulatory Therapy of Low Bone Metabolism is Osteoporosis with (1-38)hPTH and Diphosphonate EHDP,”Klinische Wochen Schrift, vol. 66, 976-984 (1988).
Cosman, F., et al, “Estrogen Protection against Bone Resorbing Effects of Parathyroid Hormone Infusion,”Annals of Internal Medicine, vol. 118, No. 5, 337-343 (1993).
Ejersted, C. et al., “Human Parathyroid Hormone (1034) and (1084) Increase the Mechanical Strength and Thickness of Cortical Bone in Rats,”Journal of Bone and Mineral Research, vol. 3, No. 9, 1097-1101 (1993).
Jerome, C.P. et al., “Effect of Treatment For 3 Months With Human Parathyroid Hormone 1-34 Peptide in Ovariectomized Cynomolgus Monkeys (Macaca fascicularis),”Bone, vol. 17, No. 4, Supplement, 415S-420S (1995).
Dempster D.W., et al., “Anabolic Actions of Parathyroid Hormone on Bone,”Endocrine Reviews, vol. 14, No. 6, 690-709, (1993).
Fujita, T., et al., “Effect of an Intermittent Weekly Dose of Human Parathyroid Hormone (1-34) on Osteoporosis: A Randomized Double-Mask Prospective Study Using Three Dose Levels,”Osteoporosis International, vol. 9, 296-306 (1999).
Hesch, R.D. et al., “Increase of Vertebral Density by Combination Therapy with Pulsatile 1-38hPTH and Sequential Addition of Calcitonin Nasal Spray in Osteoporotic Patients,”Calcified Tissue International, vol. 44, 176-180, (1989).
Hodsman, A.B. et al., “A Randomized Controlled Trial to Compare the Efficacy of Cyclical Parathyroid Hormone Versus Cyclical Parathyroid Hormone and Sequential Calcitonin to Improve Bone Mass in Postmenopausal Women with Osteoporosis,”Journal of Clinical Endocrinology and Metabolism, vol. 82, No. 2, 620-628, (1997).
Reeve, J. et al., “Anabolic Effect of Human Parathyroid Hormone Fragment on Trabecular Bone in Involutional Osteoporosis: A Multicentre Trial,”Bristish Medical Journal, vol. 280, 1340-1344, (1980).
Hesp, R. et al., “The Relationship between Changes in Femoral Bone Density and Calcium Balance in Patients with Involutional Osteoporosis Treated with Human Parathyroid Hormone Fragment (hPTH 1034),”Metabolic Bone Disease&Related Research, vol. 2, 331-334, (1981).
Reeve, J. et al., “hPTH 1-34 Treatment of Osteoporosis with Added Hormone Replacement Therapy: Biochemical, Kinetic and Histological Responses,”Osteoporosis International, vol. 1, 162-170, (1991).
Reeve, J. et al., “Human Parathyroid Peptide Treatment of Vertebral Osteoporosis,”Osteoporosis International, vol. 1 Supplement, S199-203, (1993).
Slovik, D. M. et al., “Restoration of Spinal Bone in Osteoporotic Men by Treatment With Human Parathyroid Hormone (1-34) and 1,25- Dihydroxyvitamin D,”Journal of Bone and Mineral Research, vol. 1, No. 4, 377-381, (1986).
Neer, R.M. et al., “The Use of Parathyroid Hormone Plus 1, 25- dihyroxyvitamin D to Increase Trabecular Bone in Osteoporotic Men and Postmenopausal Women,”Osteoporosis, vol. 2, 829-835, (1987).
Reeve, J. et al., “Periodic Courses of Human 1-34 Parathyroid Peptide Alternating With Calcitriol Paradoxically Reduce Bone Remodelling in Spinal Osteoporosis,”European journal of Clinical Investigation, vol. 17, 421-428, (1987).
Reeve, J. et al., “Treatment of Osteoporosis with Human Parathyroid Peptide and Observations on Effect of Sodium Fluoride,” BMJ, vol. 301, 134-318 (1990).
Riggs, B.L. et al., “Formation-Stimulating Regimens Other Than Sodium Fluoride,”The American Journal of Medicine, vol. 95 supplement 5A, 5A-62S-5A-68S (1993).
Neer, D.M. et al., “Treatment of Postmenopausal Osteoporosis with Daily Parathyroid Hormone Plus Calcitriol,”Osteoporosis International, vol. 1 Supplement, S204-205, (1993).
Whitfield, J.F. et al., “Small Bone-Building Fragments of Parathyroid Hormone: New Therapeutic Agents for Osteoporosis,”TiPS, vol. 16, 382-386, (1995).
Sone, T. et al., “A Small Dose of Human Parathyroid Hormone (1034) Increased Bone Mass in the Lumbar Vertebrae in Patients with Senile Osteoporosis,”Miner Electrolyte Metab, vol. 21, 232-235 (1995).
Reginster, J.Y. et al., “Parathyroid Hormone in the Treatment of Involutional Osteoporosis: Back to the Future,”Osteoporosis International, vol. 7 Supplement 3, S163-S168 (1997).
Smith, S.Y. et al., “Effficacy of Recombinant Human Parathyroid Hormone (1-84) (rhPTH, (1-84)) in Ovariectomized Rhesus Monkeys,”Journal of Bone and Mineral Research, vol. 23, No. 5, SA456 Abstract, S633, (1998).
Finkelstein, J.S. et al., “Increases in bone density after discontinuation of long-term GnRH analog and PTH administration in women with endometriosis,”Journal of Bone and Mineral Research, vol. 23, Supplement No. 5, F459 Abstract, S518, (1998).
Finkelstein, J.S. et al., “Increases in Bone Mineral Density after Discontinuation of Daily Human Parathyroid Hormone and Gonadotriopin-Releasing Hormone Analog Administration in Women with Endometriosis,”The Journal of Clinical Endocrinology&Metabolism, vol. 84, No. 4, 1214-1219 (1999).
Reeve, J. et al., “The Therapeutic Use of Human Parathyroid Hormone Fragment (hPTH 1-34) in Osteoporosis: Optimizing the Anabolic Effect on Trabecular and Cortical Bone,”Monoclonal Antibodies and Developments in Immunoassay, Proceedings of the 3rdInternational Conference on Radioimmunoassay 1981 held in Gardone Riviera, Italy, May 6-9, 1981. 239-246.
Finkelstein, J.S. et al., “Prevention of Estrogen Deficiency-Related Bone Loss With Human Parathyroid Hormone- (1-34),”JAMA, vol. 280, No. 12, 1067-1073 (1998).
Finkelstein, J.S. et al., “Parathyroid Hormone for the Prevention of Bone Loss Induced by Estrogen Deficiency,”The New England Journal of Medicine,
Dere Willard H.
Gaich Gregory A.
Hock Janet M.
Eli Lilly and Company
Li Ruixiang
Webster Thomas D.
LandOfFree
Method of increasing bone toughness and stiffness and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of increasing bone toughness and stiffness and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of increasing bone toughness and stiffness and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3515270